KR101759828B1 - Composition for the prevention or treatment of periodontal disease - Google Patents
Composition for the prevention or treatment of periodontal disease Download PDFInfo
- Publication number
- KR101759828B1 KR101759828B1 KR1020160028866A KR20160028866A KR101759828B1 KR 101759828 B1 KR101759828 B1 KR 101759828B1 KR 1020160028866 A KR1020160028866 A KR 1020160028866A KR 20160028866 A KR20160028866 A KR 20160028866A KR 101759828 B1 KR101759828 B1 KR 101759828B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- periodontal disease
- gardenia
- treatment
- alveolar bone
- Prior art date
Links
- 208000028169 periodontal disease Diseases 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 230000002265 prevention Effects 0.000 title claims abstract description 23
- 239000000284 extract Substances 0.000 claims abstract description 96
- 210000000988 bone and bone Anatomy 0.000 claims description 31
- 241001105098 Angelica keiskei Species 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 208000007565 gingivitis Diseases 0.000 claims description 8
- 230000036541 health Effects 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 6
- 206010031240 Osteodystrophy Diseases 0.000 claims description 5
- 206010072574 Periodontal inflammation Diseases 0.000 claims description 5
- 235000013376 functional food Nutrition 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 244000111489 Gardenia augusta Species 0.000 abstract description 56
- 240000001810 Angelica gigas Species 0.000 abstract description 48
- 235000018865 Angelica gigas Nutrition 0.000 abstract description 48
- 150000001875 compounds Chemical class 0.000 abstract description 23
- 201000001245 periodontitis Diseases 0.000 abstract description 18
- 239000004480 active ingredient Substances 0.000 abstract description 17
- 238000011084 recovery Methods 0.000 abstract description 14
- 210000002997 osteoclast Anatomy 0.000 abstract description 8
- 238000004519 manufacturing process Methods 0.000 abstract description 6
- 210000001519 tissue Anatomy 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 108020004414 DNA Proteins 0.000 description 12
- 235000007516 Chrysanthemum Nutrition 0.000 description 10
- 206010061218 Inflammation Diseases 0.000 description 10
- 240000004371 Panax ginseng Species 0.000 description 10
- 238000010171 animal model Methods 0.000 description 10
- 239000003814 drug Substances 0.000 description 10
- 235000008434 ginseng Nutrition 0.000 description 10
- 230000004054 inflammatory process Effects 0.000 description 10
- 240000005250 Chrysanthemum indicum Species 0.000 description 9
- -1 C 4 alcohols Chemical class 0.000 description 8
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 8
- 229910052737 gold Inorganic materials 0.000 description 8
- 239000010931 gold Substances 0.000 description 8
- 230000003239 periodontal effect Effects 0.000 description 8
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 7
- 235000003140 Panax quinquefolius Nutrition 0.000 description 7
- 238000010240 RT-PCR analysis Methods 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000000605 extraction Methods 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000002379 periodontal ligament Anatomy 0.000 description 7
- 230000002441 reversible effect Effects 0.000 description 7
- 108060005980 Collagenase Proteins 0.000 description 6
- 102000029816 Collagenase Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229960002424 collagenase Drugs 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 210000000963 osteoblast Anatomy 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000628997 Flos Species 0.000 description 5
- 240000002045 Guettarda speciosa Species 0.000 description 5
- 235000001287 Guettarda speciosa Nutrition 0.000 description 5
- 229920002472 Starch Polymers 0.000 description 5
- 239000000654 additive Substances 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 235000019698 starch Nutrition 0.000 description 5
- 239000000080 wetting agent Substances 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 108090001005 Interleukin-6 Proteins 0.000 description 4
- 108090001007 Interleukin-8 Proteins 0.000 description 4
- 108010015302 Matrix metalloproteinase-9 Proteins 0.000 description 4
- 102100030412 Matrix metalloproteinase-9 Human genes 0.000 description 4
- 102000014128 RANK Ligand Human genes 0.000 description 4
- 108010025832 RANK Ligand Proteins 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 239000004088 foaming agent Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 230000008929 regeneration Effects 0.000 description 4
- 238000011069 regeneration method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 229940032147 starch Drugs 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 208000006386 Bone Resorption Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 102000008108 Osteoprotegerin Human genes 0.000 description 3
- 108010035042 Osteoprotegerin Proteins 0.000 description 3
- 235000002789 Panax ginseng Nutrition 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000024279 bone resorption Effects 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 229960001375 lactose Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- XXUPLYBCNPLTIW-UHFFFAOYSA-N octadec-7-ynoic acid Chemical compound CCCCCCCCCCC#CCCCCCC(O)=O XXUPLYBCNPLTIW-UHFFFAOYSA-N 0.000 description 3
- 239000002674 ointment Substances 0.000 description 3
- 230000011164 ossification Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 230000003449 preventive effect Effects 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 2
- 241000208173 Apiaceae Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
- 102000015775 Core Binding Factor Alpha 1 Subunit Human genes 0.000 description 2
- 108010024682 Core Binding Factor Alpha 1 Subunit Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 240000000249 Morus alba Species 0.000 description 2
- 235000008708 Morus alba Nutrition 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000005888 Periodontal Pocket Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 108010050808 Procollagen Proteins 0.000 description 2
- 241001107098 Rubiaceae Species 0.000 description 2
- 102000002624 Sp7 Transcription Factor Human genes 0.000 description 2
- 108010043267 Sp7 Transcription Factor Proteins 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000010072 bone remodeling Effects 0.000 description 2
- 239000004568 cement Substances 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 230000006837 decompression Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 210000004195 gingiva Anatomy 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 239000002324 mouth wash Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 108010029690 procollagenase Proteins 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 210000003689 pubic bone Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 235000010413 sodium alginate Nutrition 0.000 description 2
- 239000000661 sodium alginate Substances 0.000 description 2
- 229940005550 sodium alginate Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- 229920003169 water-soluble polymer Polymers 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- ZZPQSQFQHIGCRC-OOFFSTKBSA-N (2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-c Chemical compound [Zn].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O ZZPQSQFQHIGCRC-OOFFSTKBSA-N 0.000 description 1
- 241000254032 Acrididae Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 244000003416 Asparagus officinalis Species 0.000 description 1
- 235000005340 Asparagus officinalis Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000193388 Bacillus thuringiensis Species 0.000 description 1
- 231100000699 Bacterial toxin Toxicity 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000255789 Bombyx mori Species 0.000 description 1
- 208000020084 Bone disease Diseases 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 235000018958 Gardenia augusta Nutrition 0.000 description 1
- 235000006885 Gardenia sp Nutrition 0.000 description 1
- 244000081616 Gardenia sp Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 208000029725 Metabolic bone disease Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010049088 Osteopenia Diseases 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 101100505672 Podospora anserina grisea gene Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 244000028344 Primula vulgaris Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 244000184734 Pyrus japonica Species 0.000 description 1
- 102100025368 Runt-related transcription factor 2 Human genes 0.000 description 1
- 101710102802 Runt-related transcription factor 2 Proteins 0.000 description 1
- 240000004534 Scutellaria baicalensis Species 0.000 description 1
- 235000017089 Scutellaria baicalensis Nutrition 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000131415 Zanthoxylum piperitum Species 0.000 description 1
- 235000008853 Zanthoxylum piperitum Nutrition 0.000 description 1
- 244000273928 Zingiber officinale Species 0.000 description 1
- 235000006886 Zingiber officinale Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000001785 acacia senegal l. willd gum Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 229940097012 bacillus thuringiensis Drugs 0.000 description 1
- 239000000688 bacterial toxin Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 239000000551 dentifrice Substances 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 235000002864 food coloring agent Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 235000008397 ginger Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000010440 gypsum Substances 0.000 description 1
- 229910052602 gypsum Inorganic materials 0.000 description 1
- 210000004209 hair Anatomy 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 230000001744 histochemical effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 210000001847 jaw Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124595 oriental medicine Drugs 0.000 description 1
- 208000005368 osteomalacia Diseases 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 238000005191 phase separation Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920002503 polyoxyethylene-polyoxypropylene Polymers 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000019814 powdered cellulose Nutrition 0.000 description 1
- 229920003124 powdered cellulose Polymers 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000006860 root resorption Diseases 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 239000003352 sequestering agent Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 210000004872 soft tissue Anatomy 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- 238000012876 topography Methods 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/232—Angelica
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/74—Rubiaceae (Madder family)
- A61K36/744—Gardenia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/312—Foods, ingredients or supplements having a functional effect on health having an effect on dental health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The present invention provides a composition for preventing, ameliorating or treating periodontal disease, which comprises Angelica gigas, Gardenia and a golden compound extract as an active ingredient.
The composition comprising the complex extract according to the present invention as an active ingredient inhibits the production of osteoclasts, induces recovery of cementum and gingival tissue, and significantly reduces the adjustment distance due to periodontitis, thereby remarkably improving the prevention and treatment of periodontal disease Lt; / RTI >
Description
The present invention relates to a composition comprising, as an active ingredient, an extract of Angelica keiskei, a gardenia and a golden compound for preventing and treating periodontal disease, or a combination extract of Angelica keiskei, Gardenia sp.
The teeth are the hardest hard tissue in the human body and are supported on the alveolar bone. The alveolar bone is firmly attached to the base bone of the jaw, and the 2-3 mm portion immediately adjacent to the root is called a periodontal bone, but the alveolar bone generally refers to both the hard tissue including the periodontal bone. Alveolar bone is gradually lowered with age, and tooth root is exposed. In addition, when the tooth is lost, the alveolar bone gradually disappears. These oral alveolar bone attaches and supports the teeth by a layer of undifferentiated mesenchymal cells called periodontal ligaments with an average thickness of about 0.2 mm and distributes the force to the alveolar bone so that the teeth can buffer during food chewing And the sense of teeth is transmitted to the alveolar bone through the periodontal ligament. In addition, periodontal ligaments are structured to adapt to pressure, continuing bone remodeling, without destroying the structure and function of the entire fiber, continuing to layers of undifferentiated mesenchymal cells. Undifferentiated mesenchymal cells in periodontal ligaments are moved to adjacent tissues, moving to the alveolar bone to perform alveolar bone remodeling and, on the other hand, move to the teeth to produce collagen fibers, which are constantly modified to hold the teeth more tightly. These teeth are allied with osteoblast-induced bone formation and osteoclast-induced bone resorption in the alveolar bone, and are maintained in balance through continuous remodeling.
Periodontal diseases include gingivitis and periodontitis, which affect teeth and gingiva supporting the teeth. Gingivitis is an early periodontal disease that causes inflammation of the soft tissues of the gingiva, and its symptoms are relatively light and the recovery is reversible. Periodontitis is a condition in which gingivitis is not treated and the inflammation progresses to the gums and around the pubic bone. When the chronic inflammatory reaction stimulated by the bacterial toxin develops, the periodontal pocket is formed between the gums and the teeth and the periodontal pocket is formed. Deepening of the depth of the periodontal ligament results in inflammation of the periodontal ligament and bone loss. In addition, osteoblast-induced bone formation and osteoclast-induced bone resorption in the alveolar bone, when the bone mass is reduced below a certain limit due to various factors, causes alveolar bone disorder such as osteoporosis.
Treatment of periodontal disease has been based on the establishment of improved oral hygiene in patients, non-surgical or surgical calculus removal, root resorption, gingival curettage, and regeneration of periodontal tissue using neoadjuvant. However, these surgical treatment methods are difficult to treat, effective treatment is difficult, and the disease is limited to the treatment that is performed when the disease progresses rather than the prevention, and most cases are chronic when not treated. In addition, systemic antibiotics and local sustained release agents have been used as adjunctive therapies. However, excessive release of drugs to unnecessary sites has resulted in side effects, and a case in which periodontal disease bacteria showing resistance to recently used antibiotics have been isolated It is reported that it has a serious problem. In addition, periodontal disease is characterized by multiple factors such as loss of alveolar bone, inflammation, and periodontitis bacteria such as Jinji valis unlike general inflammation and arthritis. Therefore, periodontal disease is caused by antibacterial and anti-inflammatory, Although a complex treatment method is required, there is no developed drug or therapeutic method for such treatment.
Under such circumstances, it is necessary to develop a drug or a therapeutic agent capable of effectively treating periodontal disease.
The present invention provides a pharmaceutical composition for the prevention and treatment of periodontal disease, which comprises Angelica keiskei, Gardenia and a golden compound extract as an active ingredient.
The present invention also provides an oral composition for the prevention and treatment of periodontal disease, comprising the extract of Angelica gigas, gardenia, and a golden compound as an active ingredient.
The present invention also provides a composition for external use for oral use comprising Angelica gigas, Gardenia and a golden compound extract as an active ingredient.
In addition, the present invention provides a health functional food for prevention and improvement of periodontal disease, which comprises the extract of Angelica gigas, gardenia and a golden compound as an active ingredient.
Also, it is intended to provide a pharmaceutical composition for prevention and treatment of periodontal disease, which comprises an extract of Angelica keiskei, a gardenia extract and a gold extract, and which is effective as an ingredient thereof.
Also, it is intended to provide an oral composition for prevention and treatment of periodontal disease, which comprises an extract of Angelica keiskei, a gardenia, and a golden extract and contains an extract of Angelica keiskei koidz.
Also, it is intended to provide a composition for external use for oral use, which comprises the Angelica keiskei, the gardenia,
In addition, the present invention provides a health functional food for prevention and improvement of periodontal disease, which comprises an extract of Angelica keiskei, a gardenia, and a golden extract and a extract of Angelica keiskei koidz.
The inventors of the present invention conducted research to develop a natural medicinal composition having a therapeutic and preventive effect for periodontal disease, and found that the extracts of Angelica gigas, Gardenia and Golden complex, especially Angelica gigas, Gardenia and Golden extract, The present inventors have found that the extract has a remarkable effect on the treatment and prevention of periodontal disease and completed the present invention.
The extract of the present invention is a preventive and therapeutic agent for periodontal disease, which has no side effects and is a safe natural agent for preventing periodontal disease using Angelica keiskei, ginger, gold, chrysanthemum and white paper. It is a complex extract of Angelica gigas, When used, have remarkable preventive and therapeutic effects as compared with individual single extracts.
In particular, when Angelicae gigantis, Gardenia, and Golden extract are added to the extracts of Chuncheon and Bleach, they have an advantage in that they have a synergistic effect on regeneration, recovery and anti-inflammatory effects of pubic bone tissue.
In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing and treating periodontal disease, which comprises Angelica gigas, Gardenia, and a golden compound extract as an active ingredient. The present invention provides a pharmaceutical composition for preventing and treating periodontal disease, which comprises an extract of Bombyx mori, a gardenia extract and a gold extract as an active ingredient.
The Angelica gigantis, the gardenia, and the golden compound extract of the present invention have a remarkable effect on the prevention and treatment of periodontal disease by inhibiting the osteoclast formation, inducing the recovery of cementum and gum tissue, and decreasing the adjusted distance of the teeth due to periodontitis. In addition, by containing more than 1000 mg of Bacillus thuringiensis in the gastric juice extract, prophylactic and therapeutic effects of periodontal disease become remarkable through gastric effect.
In the present invention, Angelica gigas is the root of Angelica gigas ( Angelica gigas ) belonging to the family Umbelliferae . Stems and leaf residues remain from the coarse and short main roots. The length of the main muscle is about 3 ~ 7cm, the diameter is 2 ~ 5cm and the length of the branch root is 15 ~ 20cm. Outer surface is light yellow to dark brown, and the main and branch roots have many vertical wrinkles and some have horizontal wrinkles. The folded surface is flat and the neck and skin are distinguished by the cambium. The skin around the throat and cambium is dark yellow while the rest is white. There is a peculiar smell, and the taste is sweet with a little writing.
In the present invention, Gardenia jasminoides belongs to the family Rubiaceae It is a ripe fruit of Japanese gardenia, and it is distributed in Japan, Taiwan and China. It grows up to 4m in height. Leaves are opposite to each other and are oval or obovate, with both ends pointed, flat edge, 3 ~ 15cm long. It is distributed in Japan, Taiwan and China. It is believed that it was imported from China 500 years ago in China. Fruit is effective as a medicine in oriental medicine because it has effects of fever, ejaculation, topography, and inflammation. It is used for symptoms such as inflammatory diseases, hepatitis, jaundice, and hematemesis.
In the present invention, gold (Scutellaria baicalensis Georgi ) is the same as the root of the sparrow grass belonging to the Lamiaceae (Labiatae). It is conical, twisted and bent with roots, 8 ~ 25cm long and 1 ~ 3cm in diameter. Outer surface is yellowish-brown to dark yellow, and lump-like fine roots are sparse. On the upper side there are relatively rough, twisted, curved vertical wrinkles or irregular net patterns. The vagina is hard, fragile and easy to cut. The cut surface is yellow and the center is reddish brown. The old age is decayed or empty in the center of the roots and dark brown to reddish brown. It is distributed in China and Korea.
In the present invention, the white paper ( Angelica dahurica ) is a generic name indicating the root portion of the copper band belonging to the Umbelliferae. The roots are pale yellowish brown, but they are hypertrophied, and when they fall down, they become ligneous and die. As a herbal medicine, it is good to have one or two years of life, but it is written that the pedicel has not come up. If you chew roots, there is a very strong taste.
In the present invention, Zanthoxylum piperitum is a fruit of a primavera belonging to Rubiaceae. It is a deciduous broad - leaved shrub belonging to. It is a perennial vine plant and has an orange fat root. The stems that hang many branches are clumpy and have small spines that are pointing downward on the hairs. Four leaves of each node are in the shape of a heart with a cross-shaped leaf. The leaves have long petiole and the edges are plain. On the back side of the leaf, 3 ~ 7 lines of parallel veins can be seen. There are small thorns like hooks on the leaf veins together with petiole. The flowers bloomed in the inside and outside of the diameter of 3.5mm are gathered together in the tips of the branches and the axilla of the leaves, and have five petals. After the flower has been cut, the two fruits are rounded together and they are darkened as they are ripe.
In the present invention, periodontal disease includes gingivitis, periodontal inflammation, alveolar bone breakage, or alveolar bone osteodystrophy, and is preferably periodontitis. In addition, the alveolar bone formation disorder includes alveolar bone osteoporosis, alveolar bone osteomalacia, or alveolar bone osteopenia.
In the present invention, the extraction method such as hot water extraction, immersion extraction, reflux cooling extraction and ultrasonic extraction can be used. The number of times of extraction is preferably 1 to 5 times, more preferably 3 times, but is not limited thereto. It is preferable to use a vacuum decompression concentrator or a vacuum rotary evaporator for the decompression concentration, but the present invention is not limited thereto. By such concentration, the extract of Angelica gigas, Gardenia and Golden complex is extracted in liquid or powder form. The extract of Angelica gigas, Gardenia and Golden complex can be obtained by extracting with an extraction solvent selected from the group consisting of water, an alcohol having 1 to 4 carbon atoms, and an aqueous solution of an alcohol having 1 to 4 carbon atoms. Preferably, the extraction solvent may be selected from the group consisting of water, C 1 to C 4 alcohols, and mixed solvents thereof. The extraction can be carried out at room temperature for 1 to 7 days, preferably for 3 days. It may also be carried out under shading and / or warming (e.g., warming) conditions, if desired. The amount of the extracting solvent is 2 to 15 times the weight of Angelica grisea, Gardenia and the golden dry weight. The ginseng, gardenia, and golden complex extract of the present invention have an amount of 0.1 wt% to 95 wt% based on the total weight of the ginseng, gardenia, and golden complex extract. The compound extract according to the present invention may be separately extracted and mixed, or the three kinds of drugs may be mixed and extracted.
In addition, it can be extracted in the same manner as above with the addition of Angelica gigas, Gardenia, and gold to white paper and perennial. The above five kinds of medicines can be extracted by separately extracting each medicament and mixing them, or by mixing the above five medicines.
The pharmaceutical composition of the present invention may further include a pharmaceutically acceptable additive. Examples of the pharmaceutically acceptable additives include starch, gelatinized starch, microcrystalline cellulose, lactose, povidone, colloidal silicon dioxide, calcium hydrogen phosphate, Wherein the starch is selected from the group consisting of lactose, mannitol, sugar, arabic gum, pregelatinized starch, cornstarch, powdered cellulose, hydroxypropyl cellulose, opaques, sodium starch glycolate, carnauba wax, synthetic aluminum silicate, stearic acid, magnesium stearate, Calcium, white sugar, dextrose, sorbitol and talc may be used.
The pharmaceutically acceptable additives according to the present invention are preferably included in an amount of 0.1 to 90 parts by weight based on 100 parts by weight of the combined extract, but are not limited thereto.
That is, the pharmaceutical composition of the present invention can be administered in various formulations of oral and parenteral administration in actual clinical administration. In the case of formulation, a diluent such as a filler, an extender, a binder, a wetting agent, a disintegrant, May be formulated using excipients. Solid formulations for oral administration include tablets, pills, powders, granules, capsules and the like, which may contain at least one excipient such as starch, calcium carbonate, sucrose, , Lactose, gelatin, and the like. In addition to simple excipients, lubricants such as magnesium stearate talc may also be used. Examples of the liquid preparation for oral use include suspensions, solutions, emulsions and syrups, and various excipients such as wetting agents, sweetening agents, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used . Formulations for parenteral administration may include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, and freeze-drying agents. Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent.
The pharmaceutical composition of the present invention may be orally administered or parenterally administered according to the desired method, and may be administered orally or parenterally in the case of parenteral administration by external or intraperitoneal injection, rectal injection, subcutaneous injection, intravenous injection, intramuscular injection, It is desirable to select the method. The dosage varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate, and disease severity.
The dosage of the pharmaceutical composition of the present invention varies depending on the patient's body weight, age, sex, health condition, diet, administration time, administration method, excretion rate and severity of disease, Kg, preferably 0.01 to 100 mg / kg, and can be administered 1 to 6 times a day.
The present invention provides an oral composition for prevention and improvement of periodontal disease comprising Angelica gigas, Gardenia, and a golden compound extract as an active ingredient. The present invention provides an oral composition for prevention and improvement of periodontal disease, which comprises as an active ingredient, white ginseng and mulberry extract added to Angelica gigas, Gardenia and Golden extract.
In the present specification, the "oral composition" is a composition which is orally administered with inhibition of differentiation of osteoclasts, reduction of cementum and gum tissue recovery distance, and the like. In the oral composition of the present invention, the formulations may be formulated into, for example, films, toothpastes, mouthwashes, ointments, sprayings, dressing solutions, coatings, dental floss or periodontal pouches.
The oral composition of the present invention may contain a wetting agent, a foaming agent, a preservative, a sweetening agent, an aging agent, a water-soluble polymer, a fragrance, and other components in addition to the above extract as an active ingredient. The additive according to the present invention is preferably contained in an amount of 0.1 to 90 parts by weight based on 100 parts by weight of the combined extract, but is not limited thereto.
The wetting agent may be at least one selected from the group consisting of polyhydric alcohols such as glycerin, sorbitol solution, amorphous sorbitol solution, polyethylene glycol and propylene glycol as a component for suppressing the evaporation of water in the oral composition.
The foaming agent has an effect of emulsifying or solubilizing a water-soluble component and an oil-soluble component in the composition, and has a cleaning effect in the oral cavity. Examples of the foaming agent include sodium lauryl sulfate, sodium N-lauroylsartocate, N- Anionic surfactants such as sucrose fatty acid esters, polyoxyethylene hydrogenated castor oil, sorbitan fatty acid esters, polyoxyethylene polyoxypropylene copolymers, and the like may be mixed and used.
The preservative is a component for prolonging the preservation period, and methyl paraoxybenzoate, benzoic acid, sodium benzoate and the like can be used.
The sweetener and / or fragrance may be saccharin sodium, aspartame, stevioside, licorice acid, and the like. Examples of the sweetener include peppermint, spearmint oil, Menthol, carbo- nons, anethole, and augenol.
The thickening agent is a component which prevents phase separation depending on time by combining the water-insoluble inorganic powder component and the liquid component in the composition and gives a viscosity to the composition. Examples of the component include carboxymethyl cellulose (CMC), carrageenan, sodium alginate, Rubber, xanthan gum, other gums and the like may be mixed and used.
The water-soluble polymer may be selected from the group consisting of hydroxypropyl cellulose-Klucel (TM), hydroxypropyl methylcellulose, hydroxyethyl cellulose, ethyl cellulose, carboxymethylcellulose, dextran Dextran, gaur-gum, polyvinyl pyrrolidone (PVP), pectins, starches, gelatin, casein, sodium alginate, polyethlyene glycol, , Polyvinyl glycol, and the like may be used in combination.
As other additives, stabilizers such as sodium citrate for pH control, fluorinating agents having a cavity inhibiting function, astringent agents such as zinc chloride, and food colors such as blue No. 1 can be used.
Further, the present invention provides a composition for oral use for external use containing oral ginseng, gardenia and a golden compound extract as an active ingredient. Preferably, the composition for external use for oral use is provided by adding white ginseng and ginseng extract to Angelica gigas, Gardenia, and Golden extract and containing it as an active ingredient.
Specifically, the oral composition for oral use may be used for periodontal disease, and the periodontal disease is as described above.
The external preparation for oral use is not particularly limited but may be preferably prepared in the form of an ointment, a lotion, a spray, a patch, a cream, a powder, a suspension, a gel or a gel. Preferably a film, a dentifrice, a mouthwash solution, an ointment, a spray, a dressing solution, an application agent, a dental floss or a periodontal tissue. In the case of using the external preparation for oral use of the present invention, it is further possible to use a solubilizer, a thickening agent and a gelling agent, a softening agent, an antioxidant, a suspending agent, a stabilizer, a foaming agent, a fragrance, Such as any of the other ingredients commonly used in oral topical agents such as emulsifiers, emulsifiers, fillers, sequestering and chelating agents, preservatives, vitamins, blocking agents, wetting agents, essential oils, dyes, pigments, hydrophilic or lipophilic active agents, And may contain commonly used adjuvants.
In addition, the present invention provides a health functional food for preventing and improving periodontal disease, which comprises Angelica gigas, Gardenia and a golden compound extract as an active ingredient. The present invention provides a health functional food for prevention and improvement of periodontal disease, which comprises as an active ingredient, white ginseng and mulberry extract added to Angelica gigantosa, Gardenia and Golden extract.
The present invention can be used as it is or in combination with other food or food ingredients, and can be suitably used according to conventional methods.
There is no particular limitation on the kind of the food. Examples of the foods to which the compound extract can be added include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramen and other noodles, gums and ice cream, various soups, drinks, tea, , An alcoholic beverage and a vitamin complex, and includes all the health foods in a conventional sense.
In addition to the above, the complex extract of the present invention may further contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and salts thereof, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, , A carbonating agent used in carbonated drinks, and the like. In addition, the complex extract of the present invention may contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks. These components may be used independently or in combination.
The composition comprising the complex extract according to the present invention as an active ingredient inhibits the production of osteoclasts, induces recovery of cementum and gingival tissue, and significantly reduces the adjustment distance due to periodontitis, thereby remarkably improving the prevention and treatment of periodontal disease Lt; / RTI >
FIG. 1 shows the result of measuring the degree of alveolar bone loss and confirming the restoration effect of tooth damage by treating Angelica gigas, Gardenia, and a golden compound extract.
FIG. 2 shows the results of RT-PCR analysis of changes in the expression of pro-collagen and MMP-9 according to the treatment of Angelica gigas, Gardenia, and a golden compound extract.
FIG. 3 shows the results of RT-PCR measurement of changes in expression of inflammation-related factors by treating Angelica gigas, Gardenia, and a golden compound extract.
FIG. 4 shows the result of western blot analysis of changes in osteoblast proliferation and osteoclast differentiation-related factors treated with Angelica gigas, Gardenia, and a golden compound extract.
FIG. 5 shows the results of in vivo restoration of tooth damage and measurement of alveolar bone loss by treating the combined extracts of Angelicae gigantis, Chinese ginseng, Chinese ginseng, white ginseng and Chinese ginseng.
FIG. 6 shows the results of examining the cementum recovery effect and the gum tissue regeneration effect by treating the extract of Angelica gigas Nakai, Gardenia japonica, Golden, White and Chrysanthemum.
Advantages and features of the present invention and methods of achieving them will become apparent with reference to the embodiments described in detail below. The present invention may, however, be embodied in many different forms and should not be construed as being limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art. Is provided to fully convey the scope of the invention to those skilled in the art, and the invention is only defined by the scope of the claims.
< Manufacturing example > Manufacture of Angelica gigas, Gardenia and Golden complex extract
(Origin: China, Origin: Domestic Origin: Domestic Origin: Domestic Origin: Omni Herb) and Chinja (Origin: China) Origin: Domestic, purchased from: Omni Herb) The extracts were prepared by dissolving 100 mg of the lyophilized product of the test substance in 1 mL of distilled water.
Based on these individual extracts, the extracts of Angelica gigas, Gardenia and Golden complexes were prepared at 100 mg / mL, and the extracts of Angelica gigas, Gardenia, Golden, White and Chrysanthemum were also prepared at 100 mg / mL.
< Example 1> According to the treatment of Angelica gigas, Gardenia and Golden complex extract in periodontal disease model Periodontal disease Confirm recovery effect
Sprague Dawley rats were bred at a temperature of 22-24 ° C and a relative humidity of 55-60% to evaluate the effects of Angelica gigas, Grasshopper and Golden Composite Extracts on alveolar bone resorption. Feeds of experimental animals were fed with solid feed (Raon Bio, Korea), and feed and water were constantly consumed.
The experimental animals were divided into three groups: 1) normal group (NL) that did not cause periodontitis; 2) an experimental group (L) that caused periodontitis and no drug administration; 3) periodontal disease; 3 mg / mL of Angelica gigas (LF3), and 4) combined treatment group (LF300) in which 300 mg / mL of Angelica keiskei, Chinese gardenia, and a golden compound extract (preparation example) were administered.
The periodontal ligament was knotted so that the dental floss was inserted between the first and second molars, and then treated with 100 μL of the experimental material in both molars that were tied together daily for 2 weeks.
After removal of the surrounding tissues of the mandible after the sacrifice of the experimental animals, the recovery effect of periodontal disease according to the treatment of Angelica gigas, Gardenia, and the golden compound extract was examined through methylene blue staining and the degree of alveolar bone loss was measured and shown in FIG.
As can be seen in FIG. 1, significant gingival damage was noted in the experimental group (L) in which periodontitis was induced compared to the normal control group (NL). However, it was confirmed that these injuries were greatly reduced in alveolar bone damage according to the treatment of Angelica gigas, Gardenia and Golden composite extract (LF3, LF300). In addition, it was confirmed that the degree of alveolar bone loss was greatly decreased according to the treatment of Angelica gigas, Gardenia and Golden complex extract (LF3, LF300).
From the above results, it was confirmed that the extract of Angelica gigas, Gardenia, and the golden compound was effective for the prevention and treatment of periodontal disease.
< Example 2> According to the treatment of Angelica gigas, Gardenia and Golden complex extract in periodontal disease model Collagenase Confirm inhibitory activity
In periodontal disease, periodontal tissue composed of collagen is degraded by collagenase, a collagenase, and collagen. Inhibition of collagenase is important in the regeneration and recovery of periodontal tissue composed of collagen.
Thus, by using the animal model of periodontal disease of Example 1, collagenase inhibitory activity by the treatment of Angelica gigas Nakai, gardenia and golden compound extract was confirmed by RT-PCR.
The extracted gum tissue was pulverized with a homogenizer using the Trizol method and 1 μg of RNA was synthesized by RT-PCR (reverse transcriptase-polymerase chain reaction). The nucleotide sequence of the PCR primer for each gene is as follows.
Experimental results of the RT-PCR are shown in FIG. 2, and their relative numerical values are shown in FIGS. 2 (a) and 2 (b).
As shown in FIG. 2, the expression of pro-collagen was increased by the treatment of Angelica gigantosa, Gardenia, and a golden compound extract, indicating regeneration of gum tissue. However, expression of MMP-9, a collagenase degrading collagen, It was confirmed that it inhibited the denaturation of < RTI ID = 0.0 >
From the above results, the prevention and treatment of periodontal disease was confirmed by the treatment of Angelica gigas, Gardenia and Golden complex extract.
< Example 3> Inhibition of Inflammatory Factor Inhibition by Treatment of Angelica gigas, Gardenia and Golden Complex Extracts in Periodontal Animal Model
Using the animal model of periodontal disease of Example 1, the inflammation-related factors (IL-1β, IL-6 and IL-8) following the treatment of Angelica gigas Nakai,
Experimental results of the RT-PCR are shown in FIG. 3, and their relative numerical values are shown in FIGS. 3 (a) to 3 (c).
As shown in FIG. 3, the expression of IL-1β, IL-6 and IL-8, which are inflammation-related factors, was reduced in a concentration-dependent manner according to the treatment of Angelica gigas Nakai,
From the above results, the prevention and treatment of periodontal disease was confirmed by the treatment of Angelica gigas, Gardenia and Golden complex extract.
< Example 4> According to treatment of Angelica gigas, Gardenia and Golden complex extract Osteoblast Confirming inhibition of proliferation and osteoclast differentiation factor expression
Using Saos-2 cells, Osterix and Runx2 (Runt-related transcription factor 2) and RANKL (osteoclast differentiation factor associated with osteoblast proliferation promoting factor) -B ligand) and OPG (osteoprotegerin) were confirmed by Western blotting.
As shown in FIG. 4, it was confirmed that RANKL was inhibited in a concentration-dependent manner and the expression of OPG, Runx2 and Osterix was increased in a concentration-dependent manner by treatment with Angelica gigantosa, Gardenia and a golden compound extract.
From the above results, it was confirmed that the extracts of Angelica gigas, Gardenia, and Gold complex showed excellent effects on promoting the proliferation of osteoblasts and inhibiting the differentiation and production of osteoclasts, thus showing remarkable effects in the prevention and treatment of periodontal disease.
< Example 5> In the periodontal disease animal model, Angelica, Gardenia, Thousand Depending on complex extract treatment Periodontal disease Confirm recovery effect
Therapeutic effect was confirmed in the same manner as in Example 1, in order to evaluate the effect of the combined extract of Angelicae, Gardenia, Gold, White and Chrysanthemum on alveolar bone absorption. Experimental animals were divided into two groups: (1) normal group (NL), (2) periodontitis, (L), (3) periodontitis, (P100), which was administered with 100 mg / mL of combined extracts of Angelica gigas Nakai, Gijyuu, Gardenia, Gold, White and Chrysanthemum.
As can be seen in FIG. 5, significant gingival damage was noted in the experimental group (L) in which periodontitis was induced compared to the normal control group (NL). However, it was confirmed that these damages were greatly reduced according to the treatment with the extracts of Angelica gigas, Gypsum, Golden, White and Chrysanthemum complex (P1, P100). In addition, it was confirmed that the degree of alveolar bone loss was greatly decreased according to LF3, LF300 treatment of Angelica gigas, Gardenia, Golden, White and Chrysanthemum complex extracts.
< Example 6> In the periodontal disease animal model, Angelica, Gardenia, Thousand Depending on complex extract treatment cement And gum tissue recovery effect
(1) According to complex extract treatment cement Confirm change
H & E staining of the first molar was performed to assess the effect of topical application of the combined extract on the cementum of periodontal disease induced animals.
The results are shown in Fig. 6 (a). The arrow indicates the cementum, and R indicates the root of the first molar.
In the animal model prepared in Example 1, denatured cementum was observed in the experimental group (L) in which periodontitis was induced by binding the dental floss compared to the normal group (NL) which did not cause periodontitis. On the other hand, it was confirmed that cementum treated with Angelica gigas, Gardenia, Golden, White and Chrysanthemum complex extract (P1 or P100) was recovered in all groups.
(2) In combination extract treatment Gum following Identify changes in tissues (gingival tissues)
Histochemical staining of the first molar was confirmed by H & E staining to assess whether topical application of the combined extract affects the gingival tissues of periodontally induced animals.
The results are shown in Fig. 6 (b). Arrows indicate gum tissue.
In the experimental group (L), in which periodontitis was induced by binding the floss, gingival tissues were found to be resorbed compared to the normal group (NL) which did not induce periodontitis.
On the other hand, it was confirmed that the gingival tissues were recovered by treatment with the extracts of Angelica gigas Nakai, Gjiji, Golden, White and Chrysanthemum in the gingival tissues which were caused by periodontitis.
In other words, it was confirmed that the combined extract of Angelica gigas Nakai, Gijia, Golden, White and Chrysanthemum recovered denatured tooth shape by improving cementum recovery and gingival tissue recovery, and was effective in the prevention and treatment of periodontal diseases.
<110> University-Industry Cooperation Group of Kyung Hee University <120> Composition for the prevention or treatment of periodontal disease <130> P16-001-KHU <160> 12 <170> KoPatentin 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Forward Primer <400> 1 ggcatggact gtggtcatga 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH Reverse Primer <400> 2 ttcaccacca tggagaaggc 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-9 Forward Primer <400> 3 gggacgcaga catcgtcatc 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MMP-9 Reverse Primer <400> 4 tcgtcatcgt cgaaatgggc 20 <210> 5 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> Pro-collagenase Forward Primer <400> 5 tctactggcg aaacctgtat ccg 23 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Pro-collagenase Reverse Primer <400> 6 caaggaaggg caggcgtgat 20 <210> 7 <211> 23 <212> DNA <213> Artificial Sequence <220> IL-1beta Forward Primer <400> 7 ctctagagca ccatgctaca gac 23 <210> 8 <211> 21 <212> DNA <213> Artificial Sequence <220> IL-1beta Reverse Primer <400> 8 tggaatccag gggaaacact g 21 <210> 9 <211> 23 <212> DNA <213> Artificial Sequence <220> <223> IL-6 Forward Primer <400> 9 cggagaggag acttcacaga gga 23 <210> 10 <211> 21 <212> DNA <213> Artificial Sequence <220> <223> IL-6 Reverse Primer <400> 10 ggagagcatt ggaaattggg g 21 <210> 11 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-8 Forward Primer <400> 11 tgtgggaggc tgtgtttgta 20 <210> 12 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> IL-8 Reverse Primer <400> 12 acgagaccag gagaaacagg 20
Claims (10)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160028866A KR101759828B1 (en) | 2016-03-10 | 2016-03-10 | Composition for the prevention or treatment of periodontal disease |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160028866A KR101759828B1 (en) | 2016-03-10 | 2016-03-10 | Composition for the prevention or treatment of periodontal disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101759828B1 true KR101759828B1 (en) | 2017-07-20 |
Family
ID=59443235
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160028866A KR101759828B1 (en) | 2016-03-10 | 2016-03-10 | Composition for the prevention or treatment of periodontal disease |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101759828B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190027440A (en) * | 2017-09-07 | 2019-03-15 | 태이생명과학 주식회사 | Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Enzyme Isolated from Aspergillus niger as Active Ingredient |
| KR20190142510A (en) * | 2018-06-18 | 2019-12-27 | 태이생명과학 주식회사 | Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Aspergillus niger as Active Ingredient |
| KR20240041381A (en) | 2022-09-21 | 2024-04-01 | 부산대학교 산학협력단 | Composition for the prevention or treatment of periodontal disease |
-
2016
- 2016-03-10 KR KR1020160028866A patent/KR101759828B1/en active IP Right Grant
Non-Patent Citations (1)
| Title |
|---|
| 배준열 기자, 메디포뉴스, "한의사가 개발한 한방 풍치 전문치약 출시" (2012.12.03.)* |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20190027440A (en) * | 2017-09-07 | 2019-03-15 | 태이생명과학 주식회사 | Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Enzyme Isolated from Aspergillus niger as Active Ingredient |
| KR102022006B1 (en) * | 2017-09-07 | 2019-09-18 | 태이생명과학 주식회사 | Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Enzyme Isolated from Aspergillus niger as Active Ingredient |
| KR20190142510A (en) * | 2018-06-18 | 2019-12-27 | 태이생명과학 주식회사 | Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Aspergillus niger as Active Ingredient |
| KR102166701B1 (en) * | 2018-06-18 | 2020-10-16 | 스노우화이트팩토리(주) | Composition for Preventing or Treating Periodontal Disease Comprising Scutellaria Extract treated by Aspergillus niger as Active Ingredient |
| KR20240041381A (en) | 2022-09-21 | 2024-04-01 | 부산대학교 산학협력단 | Composition for the prevention or treatment of periodontal disease |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20180108331A (en) | Method for improving periodontitis and alveolar bone loss of complex extracts of Moringa leaf and Eucommia Bark by anti-bacterial, antioxidant, anti-inflammatory, antioxidant effects and inhibition of alveolar bone loss | |
| KR101759828B1 (en) | Composition for the prevention or treatment of periodontal disease | |
| KR20190094987A (en) | Composition for prevention or treatment of oral disease comprising Ginkgo biloba extract | |
| CN110613801B (en) | Oral composition for preventing or improving oral diseases and use thereof | |
| KR102636026B1 (en) | Composition for prevention or trreatment of dental disease comprising an extract of Thalictrum aquilegiifolium | |
| KR20170103476A (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
| KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| KR102177066B1 (en) | Composition for prevention or treatment of oral disease comprising Epimedium Herb extract | |
| KR101978742B1 (en) | Composition for improving sleep comprising natural herbal medicine materials | |
| KR20220105707A (en) | Composition comprising Ginseng, Red Ginseng, Sophora, Licorice and Coptis extract thereof for preventing or treating of periodontitis as an effective component | |
| KR101768271B1 (en) | Composition for the prevention or treatment of periodontal disease comprising extract of Siegesbeckiae herbs | |
| KR102408893B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| KR20140115228A (en) | Composition for prevention or treatment of hair loss comprising oriental herbal extracts | |
| KR20160126672A (en) | Composition for the prevention or treatment of periodontal disease | |
| KR102380075B1 (en) | Composition for preventing or treating oral disease comprising extracts of Stewartia pseudocamellia Maxim. | |
| KR20180047704A (en) | Composition for prevention or treatment of oral disease comprising Scutellaria baicalensis extract | |
| KR101768272B1 (en) | Composition for the prevention or treatment of periodontal disease comprising extract of Siegesbeckiae herbs treated enzyme | |
| KR102231892B1 (en) | Composition for prevention or treatment of dental disease comprising an extract of Astilbe chinesis | |
| KR20180047705A (en) | Composition for prevention or treatment of oral disease comprising Forsythiae Fructus extract | |
| KR102115575B1 (en) | Composition for prevention or treatment of oral disease comprising extracts of Artemisiae Annuae and Bamboo salts | |
| KR20180047703A (en) | Composition for prevention or treatment of oral disease comprising Nelumbo Nucifera extract | |
| TWI472333B (en) | Oral herbal composition for the treatment of oral candidiasis | |
| KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
| KR20170103494A (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
| KR102156884B1 (en) | Composition for prevention or treatment of oral disease comprising Meliae toosendan fructus Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |